整合分子病理与组织病理学以准确评估WHO 2级脑膜瘤的生物学行为及患者预后
该研究对2010年1月1日至2020年12月31日本院手术切除的98例WHO 2级脑膜瘤患者进行Sahm等提出的分子病理风险分级(低、中、高危),分析无进展生存期(PFS)、恶性进展无生存期(MPFS)和总生存期(OS),发现分子风险分级与PFS、MPFS、OS负相关,全切除(Simpson I-III级)显著延长PFS和OS。
要点
- 98例WHO 2级脑膜瘤中,低危13例(13.2%)、中危63例(64.3%)、高危22例(22.4%)。
- 随分子风险等级升高,肿瘤复发、恶性进展和死亡率显著增加(P < 0.05)。
- 全切除(Simpson I-III级)显著延长PFS(HR 5.882)和OS(HR 2.611)。
核心结论
- Sahm等提出的分子风险分级可进一步细化WHO 2级脑膜瘤的分类,并更准确地评估其生物学行为和患者预后。
研究设计与样本
- 收集2010年1月1日至2020年12月31日本院手术切除的WHO 2级脑膜瘤患者的病历和石蜡包埋组织,共98例。
- 采用Sahm等提出的分子病理风险分级将患者分为低、中、高危,分析PFS、MPFS和OS,并进行单因素和多因素分析。
主要发现
- 98例患者中,低危13例(13.2%),中危63例(64.3%),高危22例(22.4%)。
- 随着分子风险等级升高,肿瘤复发、恶性进展和死亡率显著增加(P < 0.05)。
- 多因素分析显示,分子风险分级与PFS负相关(HR 0.018,95% CI 0.003-0.092),与MPFS负相关(HR 0.040,95% CI 0.006-0.266),与OS负相关(HR 0.088,95% CI 0.016-0.472)(P < 0.01)。
- 全切除(Simpson I-III级)显著延长PFS(HR 5.882,95% CI 2.538-13.699)和OS(HR 2.611,95% CI 1.117-7.299)(P < 0.05)。
关键数值与推荐
- 分子风险分级低危13例(13.2%)、中危63例(64.3%)、高危22例(22.4%)。
- 分子风险分级与PFS的HR为0.018(95% CI 0.003-0.092),与MPFS的HR为0.040(95% CI 0.006-0.266),与OS的HR为0.088(95% CI 0.016-0.472)(P < 0.01)。
- 全切除(Simpson I-III级)与PFS的HR为5.882(95% CI 2.538-13.699),与OS的HR为2.611(95% CI 1.117-7.299)(P < 0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A molecular pathological grading method was tested in WHO grade 2 meningiomas to judge whether this molecular grading can more accurately evaluate meningioma biological behaviour. METHODS: The medical records and paraffin-embedded tissues of surgically resected WHO grade 2 meningioma patients in our department from January 1, 2010, to December 31, 2020, were collected. The molecular pathological risk grading suggested by Sahm et al. was adopted and the patients were graded as low, intermediate and high risk. Progression-free survival (PFS), malignant progression-free survival (MPFS) and overall survival (OS) were analysed. Univariate and multivariate analysis were performed to determine the relationship between molecular risk grading and patient survival. RESULTS: Of the 98 patients, 13 (13.2%) were graded as low risk, 63 patients (64.3%) were graded as intermediate risk, and 22 patients (22.4%) were graded as high risk. With increasing molecular risk grade, the rates of tumour recurrence, malignant progression and mortality increased significantly (P < 0.05). Multivariate analysis showed that molecular risk grading was negatively associated with PFS (HR 0.018, 95% CI 0.003-0.092), MPFS (HR 0.040, 95% CI 0.006-0.266) and OS (HR 0.088, 95% CI 0.016-0.472) (P < 0.01), and gross total resection (Simpson grade I-III) significantly prolonged PFS (HR 5.882, 95% CI 2.538-13.699) and OS (HR 2.611, 95% CI 1.117-7.299) (P < 0.05). CONCLUSION: Sahm et al.'s molecular risk grading can further refine the classification of WHO grade 2 meningiomas and more accurately evaluate their biological behaviour and patient prognosis.
引用
- Zeng L, Li H, Chen R, et al. Integration of molecular pathology with histopathology to accurately evaluate the biological behaviour of WHO grade 2 meningiomas and patient prognosis. J Neurooncol. 2022. PMID: 36319796. doi:10.1007/s11060-022-04170-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。